R Retreatment in 1st Relapsed DLBCL
NCT00980304 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2009-09-21
Summary
It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6\~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.
After treatment each patient should be followed up for 2 years.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
-
Shanghai Jiao Tong University School of Medicine
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
NCT03372837 ·Status: COMPLETED ·Phase: PHASE3
-
Reduced Chemotherapy in Low Risk DLBCL
NCT02752815 ·Status: UNKNOWN ·Phase: PHASE4
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00568815 ·Status: COMPLETED ·Phase: PHASE2
-
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT01118845 ·Status: COMPLETED ·Phase: PHASE2
-
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT02628405 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213 ·Status: RECRUITING ·Phase: PHASE2
-
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
NCT04789434 ·Status: UNKNOWN ·Phase: PHASE3
-
RICE-ibrutinib in Relapsed DLBCL
NCT02955628 ·Status: UNKNOWN ·Phase: PHASE2
-
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
NCT04994626 ·Status: UNKNOWN ·Phase: PHASE2
-
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
NCT03715296 ·Status: UNKNOWN
-
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
NCT04319601 ·Status: UNKNOWN ·Phase: NA
-
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL
NCT04354402 ·Status: COMPLETED
-
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
NCT00210340 ·Status: WITHDRAWN ·Phase: PHASE1
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419 ·Status: TERMINATED ·Phase: PHASE1
-
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
NCT03736616 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
NCT00169156 ·Status: COMPLETED ·Phase: PHASE2
-
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
NCT06674096 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00244985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
NCT01902862 ·Status: TERMINATED ·Phase: PHASE2
-
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
NCT03422523 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
NCT02927925 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
NCT05814848 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4